Article
Biochemistry & Molecular Biology
Anna Koumarianou, Anastasios Ntavatzikos, David Symeonidis, Christos Vallilas, Maria Giannakakou, Georgios Papaxoinis, Spyridon Xynogalos, Ioannis Boukovinas, Stamatina Demiri, Katerina Kampoli, Georgios Oikonomopoulos, Epaminontas Samantas, Eleni Res, Nikolaos Androulakis, Georgia Vourli, Ioannis Souglakos, Michalis Karamouzis
Summary: This retrospective study examined the clinical characteristics and efficacy of FTD/TPI in patients with metastatic colorectal cancer. The results showed that FTD/TPI is effective as a third-line treatment, regardless of mutational status and tumor sidedness, by prolonging progression-free survival and overall survival.
Article
Oncology
Hong-Rui Lu, Peng-Fei Zhu, Ya-Ya Deng, Zhe-Ling Chen, Liu Yang
Summary: This study compared the efficacy and safety of different third-line therapy regimens for metastatic pancreatic cancer (mPC) patients. The results showed that third-line antitumor therapy can prolong the survival time of mPC patients. Chemotherapy combined with targeted therapy or immunotherapy had more adverse events compared to chemotherapy alone.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Keigo Chida, Daisuke Kotani, Toshiki Masuishi, Takeshi Kawakami, Yasuyuki Kawamoto, Kyoko Kato, Kunihiro Fushiki, Kentaro Sawada, Ryosuke Kumanishi, Hiromichi Shirasu, Yuki Matsubara, Satoshi Yuki, Yoshito Komatsu, Kentaro Yamazaki, Takayuki Yoshino
Summary: The study retrospectively reviewed medical records of colorectal cancer patients from four large oncology facilities in Japan, finding that patients with KRAS G12C mutation had significantly shorter survival time compared to those with non-G12C mutations. Therefore, stratified treatment targeting KRAS G12C mutation is relevant in mCRC.
Article
Oncology
Jizheng Tian, Lili Sui, Hong Wang, Xiaoyan Chen
Summary: This retrospective case series investigated the efficacy and safety of camrelizumab in the treatment of small cell lung cancer. The study found potential benefits of camrelizumab, but the conclusion is limited by the retrospective nature and small sample size. Large-scale randomized controlled trials are needed to determine its efficacy.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Ah Reum Lim, Jwa Hoon Kim, Myung Han Hyun, Yeul Hong Kim, Soohyeon Lee
Summary: This study investigated the changes in renal function among mCRC patients who received first-line chemotherapy and analyzed the prognostic factors and the effect of each chemotherapy regimen on renal function. The study found that renal function significantly decreased after 12 months of chemotherapy, with FOLFIRI + bevacizumab causing more frequent renal dysfunction. Older age, lower BMI, and baseline proteinuria were also associated with decreased renal function.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Oncology
Felix Riedel, Mara Muenker, Florian Roghmann, Johannes Breyer, Marco J. Schnabel, Maximilian Burger, Danijel Sikic, Thomas Buettner, Manuel Ritter, Kiriaki Hiller, Felix Wezel, Christian Bolenz, Friedemann Zengerling
Summary: This study examined the efficacy of vinflunine in patients who had received previous immune checkpoint inhibitor (ICI) therapy. The results showed higher overall response rate and clinical benefit rate in patients who had received ICI therapy compared to those who were ICI-naive. This suggests that vinflunine may have clinical activity in heavily pretreated patients.
Article
Pharmacology & Pharmacy
Ting Deng, Jingjing Duan, Ming Bai, Le Zhang, Hongli Li, Rui Liu, Tao Ning, Shaohua Ge, Xia Wang, Yuchong Yang, Zhi Ji, Feixue Wang, Yi Ba
Summary: This retrospective study investigated the clinical characteristics and real-world treatment patterns of patients with metastatic colorectal cancer (mCRC) at Tianjin Medical University Cancer Institute and Hospital from 2013 to 2020. The majority of patients chose chemotherapy combined with or without targeted therapy as their third-line treatment, while anti-angiogenic monotherapy was less commonly used. Patients receiving chemotherapy combined with or without targeted therapy had better efficacy, and the use of multiple therapies or drugs was associated with longer survival.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE
(2023)
Article
Oncology
Luc Cabel, Matthieu Carton, Barbara Pistilli, Florence Dalenc, Laurence Vanlemnens, Christelle Levy, William Jacot, Michel Debled, Agnes Loeb, Audrey Hennequin, Thibault De la Motte Rouge, Lilian Laborde, Carine Laurent, E. Chamorey, Damien Parent, Thierry Petit, Marie-Ange Mouret-Reynier, Mario Campone, Genevieve Perrocheau, Claire Labreveux, Thomas Bachelot, Mathieu Robain, Florence Lerebours
Summary: This study aimed to identify predictive factors of outcome after third-or fourth-line chemotherapy in metastatic triple-negative breast cancer patients. Factors such as PFS, number of metastatic sites, and metastasis-free interval were found to influence overall survival, with prognostic nomograms achieving a moderate level of accuracy.
Article
Oncology
Yoichiro Yoshida, Takeshi Yamada, Hirohiko Kamiyama, Chihiro Kosugi, Keiichiro Ishibashi, Hiroshi Yoshida, Hideyuki Ishida, Satoru Yamaguchi, Hidekazu Kuramochi, Atsuko Fukazawa, Hiromichi Sonoda, Kazuhiko Yoshimatsu, Akihisa Matsuda, Suguru Hasegawa, Kazuhiro Sakamoto, Toshiaki Otsuka, Keiji Koda
Summary: This study investigated the efficacy of TAS-102 and bevacizumab combination as a third-line treatment for metastatic colorectal cancer patients. The results showed that this combination therapy achieved success in prolonging progression-free survival, indicating its potential as a therapeutic option in this setting.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Donghao Xu, Yu Liu, Wentao Tang, Lingsha Xu, Tianyu Liu, Yudong Jiang, Shizhao Zhou, Xiaorui Qin, Jisheng Li, Jiemin Zhao, Lechi Ye, Wenju Chang, Jianmin Xu
Summary: This study examined the treatment patterns of regorafenib in patients with advanced metastatic colorectal cancer in China. The results showed that both regorafenib monotherapy and combination therapy provided some relief for patients, with regorafenib plus anti-PD-1 antibodies showing better progression-free survival and regorafenib plus chemotherapy yielding the greatest benefit in overall survival. The study also found no significant difference in adverse events among the three groups.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Eriseld Krasniqi, Laura Pizzuti, Maria Rosaria Valerio, Elisabetta Capomolla, Claudio Botti, Giuseppe Sanguineti, Paolo Marchetti, Elisabetta Anselmi, Silverio Tomao, Antonio Giordano, Corrado Ficorella, Katia Cannita, Lorenzo Livi, Icro Meattini, Maria Mauri, Filippo Greco, Enzo Maria Veltri, Andrea Michelotti, Luca Moscetti, Francesco Giotta, Vito Lorusso, Ida Paris, Federica Tomao, Daniele Santini, Giuseppe Tonini, Alice Villa, Vittorio Gebbia, Teresa Gamucci, Gennaro Ciliberto, Isabella Sperduti, Marco Mazzotta, Maddalena Barba, Patrizia Vici
Summary: The use of eribulin mesylate in second line treatment of mTNBC patients showed efficacy in terms of overall survival and progression free survival, with good tolerability. Longer PFS on previous first line treatment may predict better outcomes on second line treatment, and prior adjuvant chemotherapy may also positively influence the PFS on eribulin treatment.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
(2021)
Review
Oncology
Sara Cherri, Ester Oneda, Laura Zanotti, Alberto Zaniboni
Summary: Colorectal cancer is a significant health problem due to its incidence and biological complexity. Distinguishing different types of colorectal cancer based on specific characteristics is crucial for better therapeutic outcomes. The future challenge lies in studying effective combination treatments to overcome resistance mechanisms and achieve long-term treatment success. It is also important to prioritize the best therapies for first-line treatment and refine patient selection.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
In-Ho Kim, Moon Hyung Choi, In Seok Lee, Tae Ho Hong, Myung Ah. Lee
Summary: This study investigated the clinical impact of sarcopenia and skeletal muscle density (SMD) in patients with metastatic pancreatic adenocarcinoma who underwent palliative first line gemcitabine-based chemotherapy. The results showed that low SMD and low SMI were associated with poor overall survival, and the co-presence of low SMI and low SMD had more powerful prognostic implication for overall survival. Severe chemotherapy toxicity was observed more frequently in patients with sarcopenia and low SMD, suggesting that assessing skeletal muscle parameters comprehensively may be more useful as prognostic factors.
Article
Oncology
Caiyun Nie, Yunduan He, Huifang Lv, Ming Gao, Xiaohui Gao, Beibei Chen, Weifeng Xu, Jianzheng Wang, Yingjun Liu, Jing Zhao, Xiaobing Chen
Summary: This study retrospectively evaluated the efficacy and safety of anlotinib as third-line or above therapy for advanced or metastatic gastric cancer. The results showed that anlotinib monotherapy or combination therapy is a feasible treatment strategy with moderate survival and tolerable toxicity.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Lanqi Ren, Ning Ren, Yu Zheng, Yibei Yang, Qiaoping Xu
Summary: This study analyzed the cost-effectiveness of neratinib plus capecitabine (N+C) and lapatinib plus capecitabine (L+C) in HER2-positive metastatic breast cancer. The results showed that N+C was dominant in most scenarios, providing an improvement of 0.17 quality-adjusted life-years (QALYs) and reducing costs compared to L+C. The ICER was below the willingness to pay threshold, indicating that N+C is a cost-effective third-line treatment option for HER2-positive metastatic breast cancer patients.
FRONTIERS IN ONCOLOGY
(2023)
Article
Urology & Nephrology
Vito Lorusso, Boukary Kabre, Geraldine Pignot, Nicolas Branger, Andrea Pacchetti, Jeanne Thomassin-Piana, Serge Brunelle, Nicola Nicolai, Gennaro Musi, Naji Salem, Emanuele Montanari, Ottavio de Cobelli, Gwenaelle Gravis, Jochen Walz
Summary: The ANNA/C-TRUS system shows promising diagnostic performance in prostate cancer diagnosis, improving the ability of conventional TRUS. It is a valuable tool that utilizes artificial intelligence to enhance the accuracy of diagnosis, without inter-observer variability or a learning curve.
WORLD JOURNAL OF UROLOGY
(2023)
Review
Pathology
Nicola Antonio di Meo, Francesco Lasorsa, Monica Rutigliano, Martina Milella, Matteo Ferro, Michele Battaglia, Pasquale Ditonno, Giuseppe Lucarelli
Summary: Lipidomics studies the role of lipids in cancer development, with a focus on renal cell carcinoma and prostate cancer. Aberrant lipid metabolism may serve as biomarkers and therapeutic targets, and specific metabolite profiles can be used to track tumor progression in urological malignancies.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
(2023)
Review
Biochemistry & Molecular Biology
Matteo Ferro, Gennaro Musi, Michele Marchioni, Martina Maggi, Alessandro Veccia, Francesco Del Giudice, Biagio Barone, Felice Crocetto, Francesco Lasorsa, Alessandro Antonelli, Luigi Schips, Riccardo Autorino, Gian Maria Busetto, Daniela Terracciano, Giuseppe Lucarelli, Octavian Sabin Tataru
Summary: Renal cancer management poses challenges throughout the entire process from diagnosis to treatment and follow-up. The differentiation between benign and malignant tissues in cases of small renal masses and cystic lesions can be problematic, even with imaging or renal biopsy. Recent advances in artificial intelligence, imaging techniques, and genomics provide potential for helping clinicians with risk stratification, treatment selection, follow-up strategies, and prognosis. However, further prospective studies with larger patient cohorts are needed to validate previous results and implement these techniques into clinical practice.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Giuseppe Lucarelli, Giuseppe Stefano Netti, Monica Rutigliano, Francesco Lasorsa, Davide Loizzo, Martina Milella, Annalisa Schirinzi, Antonietta Fontana, Francesca Di Serio, Roberto Tamma, Domenico Ribatti, Michele Battaglia, Elena Ranieri, Pasquale Ditonno
Summary: MUC1 is overexpressed in clear cell renal cell carcinoma (ccRCC) and is associated with aggressive cancer phenotype and chemoresistance. This study found that MUC1 can regulate the immunoflammatory response in the tumor microenvironment by activating the classical pathway of the complement system and is associated with the expression of pentraxin-3 (PTX3). The results suggest that MUC1 expression can modulate the immune infiltration in the ccRCC microenvironment and promote the formation of an immune-silent microenvironment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Medicine, General & Internal
Francesco Lasorsa, Monica Rutigliano, Martina Milella, Matteo Ferro, Savio Domenico Pandolfo, Felice Crocetto, Octavian Sabin Tataru, Riccardo Autorino, Michele Battaglia, Pasquale Ditonno, Giuseppe Lucarelli
Summary: Globally, clear-cell renal cell carcinoma (ccRCC) is the most prevalent type of kidney cancer. Surgery is key in treatment, but a significant number of patients have metastatic ccRCC or experience recurrence. Molecular-target-based agents like TKIs and ICIs are recommended for advanced cancer treatment. The tumor microenvironment (TME) plays an essential role in cancer development and can be targeted for therapy. Understanding immune cell interactions with cancer and other TME elements is crucial for enhancing immunotherapies and reducing resistance.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Mattia Luca Piccinelli, Simone Morra, Stefano Tappero, Cristina Cano Garcia, Francesco Barletta, Reha-Baris Incesu, Lukas Scheipner, Andrea Baudo, Zhe Tian, Stefano Luzzago, Francesco Alessandro Mistretta, Matteo Ferro, Fred Saad, Shahrokh F. F. Shariat, Luca Carmignani, Sascha Ahyai, Derya Tilki, Alberto Briganti, Felix K. H. Chun, Carlo Terrone, Nicola Longo, Ottavio de Cobelli, Gennaro Musi, Pierre I. I. Karakiewicz
Summary: To date, guideline-recommended prognostic models predicting cancer-control outcomes in chromophobe kidney cancer patients in North America have not been validated. In this study, we validated the Leibovich 2018 and GRANT prognostic models and proposed a novel nomogram for cancer-specific survival in a large-scale North American cohort. The accuracy of the Leibovich 2018 and GRANT models was relatively low, while the novel nomogram showed higher accuracy. However, all models had limitations in certain threshold probability intervals, highlighting the need for further investigations and larger sample sizes to better predict cancer-specific survival in chromophobe kidney cancer.
Article
Oncology
Suryadipto Sarkar, Kong Min, Waleed Ikram, Ryan W. Tatton, Irbaz B. Riaz, Alvin C. Silva, Alan H. Bryce, Cassandra Moore, Thai H. Ho, Guru Sonpavde, Haidar M. Abdul-Muhsin, Parminder Singh, Teresa Wu
Summary: Accurate bladder cancer staging is crucial for determining appropriate treatment and improving patient outcome. This study presents a hybrid machine/deep learning model that improves the accuracy of bladder cancer staging using CT scans, facilitating clinical management and improving patient outcome.
Article
Oncology
Francesco Gentile, Evelina La Civita, Bartolomeo Della Ventura, Matteo Ferro, Dario Bruzzese, Felice Crocetto, Pierre Tennstedt, Thomas Steuber, Raffaele Velotta, Daniela Terracciano
Summary: The widespread use of PSA for prostate cancer diagnosis has led to high rates of overdiagnosis and overtreatment. A combination of the Prostate Health Index (PHI) and Proclarix tests can improve risk stratification of PCa patients at initial diagnosis. An artificial neural network model combining kallikrein markers in PHI and cancer-related markers in Proclarix showed increased accuracy in identifying aggressive PCa at initial diagnosis.
Review
Oncology
Carvy Floyd Luceno, Won Jin Jeon, Ravand Samaeekia, John Shin, Guru P. Sonpavde
Summary: The treatment of urothelial carcinoma is challenging due to its molecular heterogeneity and variable response to therapies. Precision medicine offers personalized treatment by using tools such as liquid biopsies and biomarkers, and improves treatment efficacy by identifying and targeting specific factors. This review discusses available tools, ongoing clinical trials, and areas for future study in the context of precision medicine.
Review
Oncology
Francesco Del Giudice, Vincenzo Asero, Eugenio Bologna, Carlo Maria Scornajenghi, Dalila Carino, Virginia Dolci, Pietro Viscuso, Stefano Salciccia, Alessandro Sciarra, David D'Andrea, Benjamin Pradere, Marco Moschini, Andrea Mari, Simone Albisinni, Wojciech Krajewski, Tomasz Szydelko, Bartosz Malkiewicz, Lukasz Nowak, Ekaterina Laukhtina, Andrea Gallioli, Laura S. Mertens, Gautier Marcq, Alessia Cimadamore, Luca Afferi, Francesco Soria, Keiichiro Mori, Karl Heinrich Tully, Renate Pichler, Matteo Ferro, Octavian Sabin Tataru, Riccardo Autorino, Simone Crivellaro, Felice Crocetto, Gian Maria Busetto, Satvir Basran, Michael L. Eisenberg, Benjamin Inbeh Chung, Ettore De Berardinis
Summary: In this systematic review and meta-analysis, the cumulative bladder cancer (BC) recurrence rates and efficacy profile of different Bacillus of Calmette-Guerin (BCG) strains were compared. The study found that BCG Tokyo 172 had the lowest recurrence rate among studies with <= 3-year recurrence-free survival (RFS). No significant difference was observed among strains in >3-year RFS outcomes. The genetically different BCG strains RIVM, Tice, and Tokyo 172 showed some potential enhanced benefits.
Review
Biochemistry & Molecular Biology
Francesco Lasorsa, Monica Rutigliano, Martina Milella, Matteo Ferro, Savio Domenico Pandolfo, Felice Crocetto, Riccardo Autorino, Michele Battaglia, Pasquale Ditonno, Giuseppe Lucarelli
Summary: Cancer stem cells (CSCs) possess several characteristics, including clonogenic ability, expression of stem cell markers, differentiation into different cell types, growth in nonadhesive spheroids, and the ability to generate tumors that reflect the heterogeneity of primary cancers. CSCs can arise from normal stem cells, progenitor cells, or differentiated cells due to genetic/epigenetic mutations or fusion with bone marrow stem cells. CSCs utilize signaling pathways similar to those involved in early embryonic development. Targeting these pathways, along with surface proteins, is important for treating RCC patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Surgery
Cinzia Bizzoca, Felicia Fiore, Fabrizio Aquilino, Salvatore Fedele, Maria Di Salvo, Giuseppe Lucarelli, Leonardo Vincenti
Summary: This study retrospectively analyzed an innovative technique of laparoscopic fenestration with simultaneous ethanol injection in 19 patients with simple hepatic cysts. The results showed that most patients experienced symptomatic relief after the surgery, and the recurrence and reintervention rates were low.
SURGERY IN PRACTICE AND SCIENCE
(2023)
Review
Biochemistry & Molecular Biology
Achille Aveta, Simone Cilio, Roberto Contieri, Gianluca Spena, Luigi Napolitano, Celeste Manfredi, Antonio Franco, Fabio Crocerossa, Clara Cerrato, Matteo Ferro, Francesco Del Giudice, Paolo Verze, Francesco Lasorsa, Andrea Salonia, Rajesh Nair, Jochen Walz, Giuseppe Lucarelli, Savio Domenico Pandolfo
Summary: Through a systematic review of scientific databases, it has been found that urinary miRNAs (umiRNAs) have potential applications in the detection, prognosis, and therapy of genitourinary cancers. In bladder cancer and urothelial carcinoma, several umiRNAs have been identified as potential non-invasive molecular biomarkers. In prostate cancer and renal cell carcinoma, umiRNAs may serve as therapeutic targets or prognostic markers. These findings suggest that umiRNAs could play an important role in the diagnosis, prognosis, and therapy of urological cancers.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Urology & Nephrology
Matteo Ferro, Felice Crocetto, Biagio Barone, Francesco del Giudice, Martina Maggi, Giuseppe Lucarelli, Gian Maria Busetto, Riccardo Autorino, Michele Marchioni, Francesco Cantiello, Fabio Crocerossa, Stefano Luzzago, Mattia Piccinelli, Francesco Alessandro Mistretta, Marco Tozzi, Luigi Schips, Ugo Giovanni Falagario, Alessandro Veccia, Mihai Dorin Vartolomei, Gennaro Musi, Ottavio de Cobelli, Emanuele Montanari, Octavian Sabin Tataru
Summary: Radiomics and artificial intelligence (AI) have the potential to improve the differentiation and characterization of various renal lesions, including distinguishing benign from malignant lesions, differentiating different subtypes of renal cell carcinoma, and predicting clinical outcomes such as Fuhrman grade and treatment response. By analyzing imaging data using neural networks, quantitative features related to contour, heterogeneity, and gray zone can be extracted, providing valuable information for diagnosis and prognosis. Standardization of scanner protocols is crucial for enhancing the diagnostic ability of imaging tools and improving the accuracy in differentiating between benign and clinically significant renal cancers.
THERAPEUTIC ADVANCES IN UROLOGY
(2023)
Article
Urology & Nephrology
Ugo G. Falagario, Anna Lantz, Ivan Jambor, Gian Maria Busetto, Carlo Bettocchi, Marco Finati, Anna Ricapito, Stefano Luzzago, Matteo Ferro, Gennaro Musi, Angelo Totaro, Marco Racioppi, Umberto Carbonara, Enrico Checcucci, Matteo Manfredi, Damiano D'Aietti, Antonio Benito Porcaro, Tobias Nordstrom, Lars Bjornebo, Marco Oderda, Francesco Soria, Pekka Taimen, Hannu J. Aronen, Ileana Montoya Perez, Otto Ettala, Michele Marchioni, Giuseppe Simone, Mariaconsiglia Ferriero, Aldo Brassetti, Luigi Napolitano, Luca Carmignani, Claudia Signorini, Andrea Conti, Giuseppe Ludovico, Marcello Scarcia, Carlo Trombetta, Francesco Claps, Fabio Traunero, Emanuele Montanari, Luca Boeri, Martina Maggi, Francesco Del Giudice, Pierluigi Bove, Valerio Forte, Vincenzo Ficarra, Marta Rossanese, Giuseppe Mucciardi, Vincenzo Pagliarulo, Alessandro Tafuri, Vincenzo Mirone, Luigi Schips, Alessandro Antonelli, Paolo Gontero, Luigi Cormio, Alessandro Sciarra, Francesco Porpiglia, Pierfrancesco Bassi, Pasquale Ditonno, Peter J. Bostrom, Emanuele Messina, Valeria Panebianco, Ottavio De Cobelli, Giuseppe Carrieri, PROMOD Study Grp
Summary: The purpose of this study was to evaluate the impact of 5-alpha-reductase inhibitors (5-ARIs) on the performance of MRI in diagnosing clinically significant Prostate Cancer (csPCa). The study found that 5-ARIs did not affect the association between PIRADS score and csPCa, but treated patients had a higher detection rate of high-grade prostate cancer.
WORLD JOURNAL OF UROLOGY
(2023)
